Evercore ISI initiates coverage on PROCEPT BioRobotics with Outperform rating

0 min read     Updated on 24 Jun 2026, 04:21 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Evercore ISI Group analyst Vijay Kumar initiated coverage on PROCEPT BioRobotics with an Outperform rating and a $30 price target, signaling a positive outlook for the NASDAQ-listed company.

powered bylight_fuzz_icon
43843896

*this image is generated using AI for illustrative purposes only.

Evercore ISI Group analyst Vijay Kumar has initiated coverage on PROCEPT BioRobotics with an Outperform rating and announced a price target of $30. The rating reflects a positive outlook on the company's performance and market position.

Analyst Rating and Price Target

The initiation of coverage provides a new benchmark for investors evaluating the stock. The Outperform rating suggests that the stock is expected to perform better than the market average.

Metric Detail
Rating Outperform
Price Target $30
Analyst Vijay Kumar
Exchange NASDAQ

PROCEPT BioRobotics is listed on NASDAQ under the ticker symbol PRCT.

What specific market trends or competitive advantages support the Outperform rating for PROCEPT BioRobotics?

How might the $30 price target influence investor sentiment and trading volume in the short term?

What upcoming milestones or product developments could drive further analyst coverage or price target adjustments?

like20
dislike

Leerink Partners downgrades Procept Biorobotics to Market Perform

0 min read     Updated on 11 Jun 2026, 09:18 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Leerink Partners analyst Mike Kratky downgraded Procept Biorobotics Corp from Outperform to Market Perform and cut the price target to $29 from $31. Procept Biorobotics shares closed at $29.09 on Wednesday.

powered bylight_fuzz_icon
42734625

*this image is generated using AI for illustrative purposes only.

Leerink Partners analyst Mike Kratky has downgraded Procept Biorobotics Corp, reducing the stock's rating from Outperform to Market Perform. The firm also adjusted its valuation expectations, lowering the price target to $29 from the previous $31. Procept Biorobotics shares closed at $29.09 on Wednesday.

The revised rating and price target reflect a shift in the analyst's outlook regarding the company's near-term performance potential relative to the broader market. This adjustment places the stock's target slightly below its current trading level.

Rating and Price Target Changes

The following table outlines the specific changes made by Leerink Partners:

Metric Previous Value New Value
Rating Outperform Market Perform
Price Target $31 $29

What specific factors led Leerink Partners to revise Procept Biorobotics' near-term performance outlook?

How might this downgrade impact investor sentiment and trading volume in the short term?

Are there upcoming clinical trials or product launches that could reverse the revised outlook?

like17
dislike
Must Read Next

Earnings

Corporate Actions

Stocks